This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Watson Pharmaceuticals' CEO Discusses Q1 2012 Results - Earnings Call Transcript

Stocks in this article: WPI

Watson Pharmaceuticals (WPI)

Q1 2012 Earnings Call

April 30, 2012 8:30 am ET

Executives

Patricia L. Eisenhaur - Vice President of Investor Relations & Corporate Communications

Paul M. Bisaro - Chief Executive Officer, President and Director

R. Todd Joyce - Chief Financial Officer, Executive Vice President, Principal Accounting Officer, Corporate Controller and Treasurer

Albert Paonessa - Chief Operating Officer of Distribution Division and Executive Vice President of Distribution Division

George Frederick Wilkinson - Executive Vice President of Global Brands

Sigurdur Oli Olafsson - Executive Vice President of Global Generics

Analysts

Michael Faerm - Crédit Suisse AG, Research Division

Randall Stanicky - Canaccord Genuity, Research Division

Timothy Chiang - CRT Capital Group LLC, Research Division

Corey B. Davis - Jefferies & Company, Inc., Research Division

Gregory B. Gilbert - BofA Merrill Lynch, Research Division

Christopher Schott - JP Morgan Chase & Co, Research Division

David G. Buck - The Buckingham Research Group Incorporated

Jami Rubin - Goldman Sachs Group Inc., Research Division

Frank H. Pinkerton - SunTrust Robinson Humphrey, Inc., Research Division

Gary Nachman - Susquehanna Financial Group, LLLP, Research Division

David Risinger - Morgan Stanley, Research Division

David Amsellem - Piper Jaffray Companies, Research Division

Marc Goodman - UBS Investment Bank, Research Division

Elliot Wilbur - Needham & Company, LLC, Research Division

Shibani Malhotra - RBC Capital Markets, LLC, Research Division

Ken Cacciatore - Cowen and Company, LLC, Research Division

Presentation

Operator

Good morning. My name is Therese, and I will be your conference operator today. At this time I would like to welcome everyone to the Watson Pharmaceuticals First Quarter Earnings Conference Call. [Operator Instructions] I would now like to turn the call over to Patty Eisenhaur. Go ahead, Patty.

Patricia L. Eisenhaur

Thank you, Therese, and good morning, everyone. I'd like to welcome you to Watson's First Quarter 2012 Earnings Conference Call. Earlier this morning, Watson issued a press release reporting its earnings for the first quarter ended March 31, 2012. The press release is available on our website at www.watson.com. Additionally, we are conducting a live webcast of this call, which will also be available on our website after the call's conclusion.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Jim Cramer and Stephanie Link reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

Jim Cramer's protégé, David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
Try it NOW
Try it NOW
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

Jim Cramer's protégé, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!

Markets

DOW 17,164.95 -251.90 -1.45%
S&P 500 1,994.99 -26.26 -1.30%
NASDAQ 4,635.24 -48.1670 -1.03%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs